Impact of discharge checklist on guidelinedirected medical therapy and mid-term prognosis in heart failure
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Despite the proven benefit of the guideline-directed medical therapy (GDMT), it remains underutilized in patients hospitalized with acute heart failure (HF). We aimed to evaluate the impact of the discharge checklist on GDMT installation and the prognosis of HF patients. Methods: This study was a single-center, observational study that included all patients admitted for HF from March 2021 to February 2023. The data were retrieved from electronic medical records and discharge checklists. A comparison was conducted between the checklist group and the non-checklist group. The primary endpoint was a composite of all-cause mortality or readmission for HF within 6 months. Results: The checklist was completed for 537 patients (checklist group) and not for 187 patients (non-checklist group). The proportion of patients to whom two or more components of GDMT were prescribed was significantly higher in the checklist group than in the non-checklist group (59.6% vs 42.2%, p < 0.001). The checklist group exhibited a significantly lower primary outcome compared to the non-checklist group (27.4% vs. 36.4%, HR 0.73, 95% CI 0.55–0.98, p = 0.036). The effect of the checklist was more prominent in HF with reduced ejection fraction (HR 0.51, 95% CI 0.34–0.77, p = 0.001) than in HF with mildly-reduced and preserved ejection fraction (HR 0.91, 95% CI 0.58–1.42, p = 0.676) (p for interaction = 0.06). Conclusions: The implementation of the discharge checklist was associated with an improvement in GDMT prescription and an improved prognosis in patients with HF with reduced ejection fraction.
Abstract
Background/Aims: Despite the proven benefit of the guideline-directed medical therapy (GDMT), it remains underutilized in patients hospitalized with acute heart failure (HF). We aimed to evaluate the impact of the discharge checklist on GDMT installation and the prognosis of HF patients. Methods: This study was a single-center, observational study that included all patients admitted for HF from March 2021 to February 2023. The data were retrieved from electronic medical records and discharge checklists. A comparison was conducted between the checklist group and the non-checklist group. The primary endpoint was a composite of all-cause mortality or readmission for HF within 6 months. Results: The checklist was completed for 537 patients (checklist group) and not for 187 patients (non-checklist group). The proportion of patients to whom two or more components of GDMT were prescribed was significantly higher in the checklist group than in the non-checklist group (59.6% vs 42.2%, p < 0.001). The checklist group exhibited a significantly lower primary outcome compared to the non-checklist group (27.4% vs. 36.4%, HR 0.73, 95% CI 0.55–0.98, p = 0.036). The effect of the checklist was more prominent in HF with reduced ejection fraction (HR 0.51, 95% CI 0.34–0.77, p = 0.001) than in HF with mildly-reduced and preserved ejection fraction (HR 0.91, 95% CI 0.58–1.42, p = 0.676) (p for interaction = 0.06). Conclusions: The implementation of the discharge checklist was associated with an improvement in GDMT prescription and an improved prognosis in patients with HF with reduced ejection fraction.
참고문헌 (25)
- Park JJ, "Heart failure statistics in Korea, 2020 : a report from the Korean Society of Heart Failure", Int J Heart Fail, 3, pp.224~236 (2021)
- Heidenreich PA, "2022 AHA", ACC, American Heart Association Joint Committee on clinical practice guidelines, pp.Circulation, 2022[DOI]
- Park CS, "J-curve relationship between corrected QT interval and mortality in acute heart failure patients", Korean J Intern Med, 35, pp.1371~1384 (2020)
- Maddox TM, "2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment : answers to 10 pivotal issues about heart failure with reduced ejection fraction : a report of the American College of Cardiology Solution Set Oversight Committee", J Am Coll Cardiol, 77, pp.772~810 (2021)
- Seo WW, "Guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction : a cohort study", BMJ Open, 10, pp.e030514~ (2020)
- Greene SJ, "Medical therapy for heart failure with reduced ejection fraction : the CHAMP-HF registry", J Am Coll Cardiol, 72, pp.351~366 (2018)
- Lee SE, "Clinical characteristics and outcome of acute heart failure in Korea : results from the Korean Acute Heart Failure Registry(KorAHF)", Korean Circ J, 47, pp.341~353 (2017)
- Basoor A, "Decreased readmissions and improved quality of care with the use of an inexpensive checklist in heart failure", Congest Heart Fail, 19, pp.200~206 (2013)
- Rismiati H, "The role of discharge checklist in guideline-directed medical therapy for heart failure patients", Korean J Intern Med, 38, pp.195~206 (2023)
- Hyun J, "Korean Society of Heart Failure guidelines for the management of heart failure : advanced and acute heart failure", Int J Heart Fail, 5, pp.111~126 (2023)
- Cho JY, "Korean Society of Heart Failure Guidelines for the management of heart failure : definition and diagnosis", Int J Heart Fail, 5, pp.51~65 (2023)
- Choi HM, "Update on heart failure management and future directions", Korean J Intern Med, 34, pp.11~43 (2019)
- Beyene J, "Determining relative importance of variables in developing and validating predictive models", BMC Med Res Methodol, 9, pp.64~ (2009)
- Mannan H, "A practical application of a simple bootstrapping method for assessing predictors selected for epidemiologic risk models using automated variable selection", Int J Stat Appl, 7, pp.239~249 (2017)
- Youn JC, "Korean Society of Heart Failure guidelines for the management of heart failure : treatment", Int J Heart Fail, 5, pp.66~81 (2023)
- Park SM, "Korean Society of Heart Failure guidelines for the management of heart failure : management of the underlying etiologies and comorbidities of heart failure", Int J Heart Fail, 5, pp.127~145 (2023)
- Tsao CW, "Heart disease and stroke statistics-2023 update : a report from the American Heart Association", Circulation, 147, pp.e93~e621 (2023)
- Shah KS, "Heart failure with preserved, borderline, and reduced ejection fraction : 5-year outcomes", J Am Coll Cardiol, 70, pp.2476~2486 (2017)
- Mebazaa A, "Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure(STRONG-HF) : a multinational, open-label, randomised, trial", Lancet, 400, pp.1938~1952 (2022)
- Fonarow GC, "Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004 : findings from Acute Decompensated Heart Failure National Registry(ADHERE)", Am Heart J, 153, pp.1021~1028 (2007)
- Atherton JJ, "Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific(ADHERE International-Asia Pacific)", J Card Fail, 18, pp.82~88 (2012)
- Kaul U, "Consensus and development of document for management of stabilized acute decompensated heart failure with reduced ejection fraction in India", Indian Heart J, 72, pp.477~481 (2020)
- Kocabaş U, "Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction", ESC Heart Fail, 10, pp.3677~3689 (2023)
- Margolin E, "Determinants of guideline-directed medical therapy implementation during heart failure hospitalization", JACC Adv, 3, pp.100818~ (2024)
- Hein AM, "Medical management of heart failure with reduced ejection fraction in patients with advanced renal disease", JACC Heart Fail, 7, pp.371~382 (2019)